Peapack Gladstone Financial Corp Trims Stock Holdings in VanEck Biotech ETF (NASDAQ:BBH)

Peapack Gladstone Financial Corp decreased its holdings in shares of VanEck Biotech ETF (NASDAQ:BBH) by 12.8% during the third quarter, HoldingsChannel reports. The fund owned 10,610 shares of the company’s stock after selling 1,553 shares during the quarter. Peapack Gladstone Financial Corp’s holdings in VanEck Biotech ETF were worth $1,882,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in BBH. Truvestments Capital LLC purchased a new position in shares of VanEck Biotech ETF in the third quarter valued at $44,000. Red Lighthouse Investment Management LLC purchased a new position in VanEck Biotech ETF during the 2nd quarter valued at about $51,000. FSA Wealth Management LLC purchased a new position in VanEck Biotech ETF during the 3rd quarter valued at about $54,000. Coastline Trust Co bought a new stake in shares of VanEck Biotech ETF during the third quarter valued at about $59,000. Finally, Wilmington Savings Fund Society FSB purchased a new stake in shares of VanEck Biotech ETF in the third quarter worth about $166,000. Hedge funds and other institutional investors own 32.05% of the company’s stock.

VanEck Biotech ETF Stock Performance

BBH stock opened at $163.42 on Friday. The firm has a 50 day moving average of $169.63 and a 200-day moving average of $172.99. VanEck Biotech ETF has a 12 month low of $151.35 and a 12 month high of $183.64.

VanEck Biotech ETF Company Profile

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.